Facilitator: Sherry Larkins, PhD, Director of International Programs and Research Sociologist, Integrated Substance Abuse Programs at the University of California, Los Angeles – Semel Institute for Neuroscience and Human Behavior

Cost: No fee

Target Audience: Physicians, nurse practitioners or other advanced practice nurses, PAs, psychologists, clinical administrators and healthcare teams.

Credit Designations Available: AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME credit, and Interprofessional Continuing Education (IPCE) credit.

Webinar Description: After the organizational and clinical components of initiating OUD treatment have been mapped out, how do we begin effective implementation? This session will map out concrete clinical and patient flow activities and consider issues of documentation, charting, and recommended metrics. We will review steps for conducting a small pilot/demonstration buprenorphine project, with regular outcomes-monitoring to ensure a smooth scale up of treatment and care for patients with OUD. This includes doing a walk-through to ensure behavioral health and prescriber staff have the certifications, knowledge and skills to deliver buprenorphine, or other pharmacotherapies, in integrated settings. We will discuss approaches for utilizing leadership and staff check-ins to get a pulse on practices, scale up, and changes needed to ensure successful expansion across all administrative and clinical staff. Finally, we will consider which metrics –immediate and long-term– are meaningful to your site, and how to gather relevant data to support federal/state reporting requirements, process improvement goals, and clinical decision-making in MOUD delivery.

Educational Objectives:

• Demonstrate skills to map out a site-specific patient flow and staff flow, including roles and tasks of staff
• Determine which metrics – immediate and long-term – are valuable to their program and how to gather relevant data
• Consider how information from their EHR can be used to support reporting requirements, process improvement goals, and clinical decision-making in MOUD delivery
• Describe how to set up protocols ensuring patient confidentiality (42 CFR, pt. 2)

Accreditation and Certification of this activity:

In support of improving patient care, this activity has been planned and implemented by Addiction Technology Transfer Center Network and American Academy of Addiction Psychiatry. American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

In 2020, AAAP also added accreditation from The American Academy of PAs (AAPA), American Psychological Association (APA), Association for Social Work Boards (ASWB) and American Dental Association (ADA).

Interprofessional Continuing Education (IPCE) Designation Statement:

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education credits for learning and change.

Physician Designation Statement

American Academy of Addiction Psychiatry designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Designation Statement

American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP’s Joint Accreditation provider #4008192. This activity is approved for up to 1 Nursing Contact Hours.

PA Designation Statement

American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for a maximum of 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.